Related references
Note: Only part of the references are listed.Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity
Nina Dumauthioz et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Steven C. Katz et al.
CANCER GENE THERAPY (2020)
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors
Kirsty Ford et al.
CANCER RESEARCH (2020)
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours
Florian Wiede et al.
EMBO JOURNAL (2020)
Interleukin-23 engineering improves CAR T cell function in solid tumors
Xingcong Ma et al.
NATURE BIOTECHNOLOGY (2020)
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
Greta Giordano-Attianese et al.
NATURE BIOTECHNOLOGY (2020)
Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands
ZeNan L. Chang et al.
NATURE PROTOCOLS (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi et al.
NATURE COMMUNICATIONS (2020)
Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours
Michael E. Coon et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Laura Strauss et al.
SCIENCE IMMUNOLOGY (2020)
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Theodore L. Roth et al.
CELL (2020)
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Ling Wu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.
Christina M. Annunziata et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking
Andrew J. Gunderson et al.
NATURE COMMUNICATIONS (2020)
A bioorthogonal system reveals antitumour immune function of pyroptosis
Qinyang Wang et al.
NATURE (2020)
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai et al.
NATURE IMMUNOLOGY (2020)
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
Johanna Theruvath et al.
NATURE MEDICINE (2020)
FROM THE ANALYST'S COUCH Cancer cell therapies: the clinical trial landscape
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies
Devikala Gurusamy et al.
CANCER CELL (2020)
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
Kevin R. Parker et al.
CELL (2020)
Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen
Santosha A. Vardhana et al.
NATURE IMMUNOLOGY (2020)
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
Preeti Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Chimeric antigen receptor -T cells with cytokine neutralizing capacity
Adrian H. J. Tan et al.
BLOOD ADVANCES (2020)
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
Shivani Srivastava et al.
CANCER CELL (2019)
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tori N. Yamamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
NR4A transcription factors limit CAR T cell function in solid tumours
Joyce Chen et al.
NATURE (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
Prasad S. Adusumilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Acetate Promotes T Cell Effector Function during Glucose Restriction
Jing Qiu et al.
CELL REPORTS (2019)
Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma
Ingunn M. Stromnes et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Alexandre Juillerat et al.
BMC BIOTECHNOLOGY (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Francesca Alfei et al.
NATURE (2019)
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C. Scott et al.
NATURE (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection
Chen Yao et al.
NATURE IMMUNOLOGY (2019)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Aude G. Chapuis et al.
NATURE MEDICINE (2019)
TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
Hyungseok Seo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Patrick A. Baeuerle et al.
NATURE COMMUNICATIONS (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion
Ansuman T. Satpathy et al.
NATURE BIOTECHNOLOGY (2019)
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
Martin W. LaFleur et al.
NATURE IMMUNOLOGY (2019)
Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity
Paramita Chakraborty et al.
CELL REPORTS (2019)
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
Songming Peng et al.
CELL REPORTS (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
Zeyu Chen et al.
IMMUNITY (2019)
Developing neoantigen-targeted T cell-based treatments for solid tumors
Tori N. Yamamoto et al.
NATURE MEDICINE (2019)
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Kathrin Renner et al.
CELL REPORTS (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Judith Feucht et al.
NATURE MEDICINE (2019)
c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn et al.
NATURE (2019)
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Jun Wei et al.
NATURE (2019)
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
Robin Parihar et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Leyuan Ma et al.
SCIENCE (2019)
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells
Lelisa F. Gemta et al.
SCIENCE IMMUNOLOGY (2019)
Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
Daniel T. Harris et al.
JOURNAL OF IMMUNOLOGY (2018)
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Christopher J. Hanley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Christopher J. Hanley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Tina Cascone et al.
CELL METABOLISM (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
Katarzyna C. Pituch et al.
MOLECULAR THERAPY (2018)
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Christine E. Brown et al.
MOLECULAR THERAPY (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Christopher W. Mount et al.
NATURE MEDICINE (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade
Natalie J. Neubert et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Sujita Sukumaran et al.
CANCER DISCOVERY (2018)
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Mauro P. Avanzi et al.
CELL REPORTS (2018)
Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions
Ashley V. Menk et al.
CELL REPORTS (2018)
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager
Anna Wing et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
Yasushi Akahori et al.
BLOOD (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Christopher W. Helsen et al.
NATURE COMMUNICATIONS (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Haiying Qin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
TGF-β-responsive CAR-T cells promote anti-tumor immune function
Andrew J. Hou et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2018)
Improving immune-vascular crosstalk for cancer immunotherapy
Yuhui Huang et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors
Luca Cassetta et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A. Beavis et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Tyrel T. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
Aaron E. Foster et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Somala Mohammed et al.
MOLECULAR THERAPY (2017)
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Yupeng Wang et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
Paola Fisicaro et al.
NATURE MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity
Patrick Ho et al.
ACS SYNTHETIC BIOLOGY (2017)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu et al.
CELL REPORTS (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Alessia Angelin et al.
CELL METABOLISM (2017)
Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease
Chirag H. Patel et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Shari Pilon-Thomas et al.
CANCER RESEARCH (2016)
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Maarten A. Ligtenberg et al.
JOURNAL OF IMMUNOLOGY (2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal et al.
CELL (2016)
The Emerging Hallmarks of Cancer Metabolism
Natalya N. Pavlova et al.
CELL METABOLISM (2016)
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Almut Brand et al.
Cell Metabolism (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion
Bertram Bengsch et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Wei Yang et al.
NATURE (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells
Christopher Ede et al.
ACS SYNTHETIC BIOLOGY (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping-Chih Ho et al.
CELL (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Shinichi Kageyama et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
Bin Zhang et al.
TUMOR BIOLOGY (2015)
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Sirkka B. Stephan et al.
NATURE BIOTECHNOLOGY (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Finding suitable targets is the major obstacle to cancer gene therapy
Steven A. Rosenberg
CANCER GENE THERAPY (2014)
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases
A. Saied et al.
CANCER GENE THERAPY (2014)
Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
Yong-Chen Lu et al.
CLINICAL CANCER RESEARCH (2014)
Memory CD8+ T Cells Use Cell-Intrinsic Lipolysis to Support the Metabolic Programming Necessary for Development
David O'Sullivan et al.
IMMUNITY (2014)
Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody-Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds
Ravit Oren et al.
JOURNAL OF IMMUNOLOGY (2014)
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Ann M. Leen et al.
MOLECULAR THERAPY (2014)
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
Oscar R. Colegio et al.
NATURE (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
David A. Nathanson et al.
SCIENCE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
HLA-Binding Properties of Tumor Neoepitopes in Humans
Edward F. Fritsch et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chih-Hao Chang et al.
CELL (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Reassessing target antigens for adoptive T-cell therapy
Christian S. Hinrichs et al.
NATURE BIOTECHNOLOGY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells
Brian J. Cameron et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
Arianna Calcinotto et al.
CANCER RESEARCH (2012)
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Christopher A. Klebanoff et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
Megan E. Prosser et al.
MOLECULAR IMMUNOLOGY (2012)
CD73: a potent suppressor of antitumor immune responses
Paul. A. Beavis et al.
TRENDS IN IMMUNOLOGY (2012)
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs)
Jennifer D. Stone et al.
ONCOIMMUNOLOGY (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Mechanisms of Leukocyte Transendothelial Migration
William A. Muller
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Matija Snuderl et al.
CANCER CELL (2011)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy
Priyadharshini Narayanan et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Mark J. Anderton et al.
TOXICOLOGIC PATHOLOGY (2011)
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
Scott Wilkie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Large double copy vectors are functional but show a size-dependent decline in transduction efficiency
Tomas J. Bos et al.
JOURNAL OF BIOTECHNOLOGY (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
Fabio Ciceri et al.
LANCET ONCOLOGY (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Death by a thousand cuts: Granzyme pathways of programmed cell death
Dipanjan Chowdhury et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Karin Fischer et al.
BLOOD (2007)
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation
C Berger et al.
BLOOD (2006)
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy
T Zhang et al.
BLOOD (2005)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin
SA Lyons et al.
GLIA (2002)
Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity
CM Bollard et al.
BLOOD (2002)
Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects
M Höckel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
